Maven Semantic: Microarray Research Database

Search Over 70,000 People and Over 5,000 Microarray Research Organisations

DUBLIN--(BUSINESS WIRE)-- Maven Semantic (http://www.mavensemantic.com) announces updates to their Microarray research database.

The new database is now available to marketing, business development, competitor intelligence, KOL, medical affairs and related departments in the life sciences sector.

The database currently tags 70,000 individuals working in Microarray. http://bit.ly/f1JreE.

Top 10 Countries for Microarray Research (ranked by number of senior Microarray researchers)

Leading organisations in Microarray research include:

  • Boston University
  • Columbia University
  • Harvard Medical School
  • Iowa State University
  • Johns Hopkins University
  • Ohio State University
  • University of Helsinki
  • University of Kentucky
  • University of Manchester
  • University of Pennsylvania
  • University of Tokyo
  • University of Toronto
  • University of Utah
  • University of Washington
  • Yale University

The database also includes pharmaceutical companies, biotech companies, CROs, hospitals, government labs and other organisations active in the Microarray research field.

Sample companies in database include:

  • Affymetrix, Inc
  • Agilent Technologies, Inc
  • Ambion, Inc
  • Amgen Inc
  • Asuragen, Inc
  • Chroma Therapeutics Ltd
  • Corixa Corporation
  • CuraGen Corporation
  • deCODE genetics, Inc
  • DuPont Company
  • Eli Lilly and Company
  • Epigenomics AG
  • F. Hoffmann-La Roche Ltd
  • Gene Logic Inc
  • Genentech, Inc
  • Geron Corporation
  • Illumina, Inc
  • Ligand Pharmaceuticals, Inc

What is Maven:

- Largest database of international medical professionals, with over 6,000,000 people and over 500,000 medical organisations;

- All records are downloadable to excel or in-house database, with email, postal address and phone contacts;

- Profile and segment the entire database using over 47,000 diseases and therapeutic area

For more information visit http://www.mavensemantic.com/



CONTACT:

Maven Semantic
Bryan McManmon
[email protected]
Ph: +353 1 4100699

KEYWORDS:   United States  Europe  Asia Pacific  North America

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Hospitals

MEDIA:

Logo
 Logo

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.